Adjuvant and Salvage Radiation Therapy After Prostatectomy

ASTRO/AUA Guideline Amendment, Executive Summary 2018

Thomas M. Pisansky, Ian M. Thompson, Richard K Valicenti, Anthony V. D'Amico, Shalini Selvarajah

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The purpose of this amendment is to incorporate newly published literature into the original American Society for Radiation Oncology/American Urological Association Adjuvant and Salvage Radiotherapy After Prostatectomy Guideline and provide an updated clinical framework for clinicians. Methods and Materials: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published between January 1990 and December 2017. Two new key questions were added: one on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation after radical prostatectomy. Results: A new statement on the use of hormone therapy with salvage radiation therapy (RT) after radical prostatectomy was added, and long-term data were used to update an existing statement on adjuvant RT. The balance of the guideline statements were reaffirmed, and references added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases were found. Conclusions: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage RT. Clinicians should discuss possible short- and long-term side effects with patients in addition to the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multidisciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.

Original languageEnglish (US)
Pages (from-to)208-213
Number of pages6
JournalPractical Radiation Oncology
Volume9
Issue number4
DOIs
StatePublished - Jul 1 2019

Fingerprint

Salvage Therapy
Prostatectomy
Radiotherapy
Guidelines
Hormones
Neoplasm Metastasis
Adjuvant Radiotherapy
Radiation Oncology
Therapeutics
Quality of Life
Radiation
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Adjuvant and Salvage Radiation Therapy After Prostatectomy : ASTRO/AUA Guideline Amendment, Executive Summary 2018. / Pisansky, Thomas M.; Thompson, Ian M.; Valicenti, Richard K; D'Amico, Anthony V.; Selvarajah, Shalini.

In: Practical Radiation Oncology, Vol. 9, No. 4, 01.07.2019, p. 208-213.

Research output: Contribution to journalArticle

Pisansky, Thomas M. ; Thompson, Ian M. ; Valicenti, Richard K ; D'Amico, Anthony V. ; Selvarajah, Shalini. / Adjuvant and Salvage Radiation Therapy After Prostatectomy : ASTRO/AUA Guideline Amendment, Executive Summary 2018. In: Practical Radiation Oncology. 2019 ; Vol. 9, No. 4. pp. 208-213.
@article{832ae0fbd79d4e9c80d069844f4ec8bf,
title = "Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018",
abstract = "Purpose: The purpose of this amendment is to incorporate newly published literature into the original American Society for Radiation Oncology/American Urological Association Adjuvant and Salvage Radiotherapy After Prostatectomy Guideline and provide an updated clinical framework for clinicians. Methods and Materials: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published between January 1990 and December 2017. Two new key questions were added: one on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation after radical prostatectomy. Results: A new statement on the use of hormone therapy with salvage radiation therapy (RT) after radical prostatectomy was added, and long-term data were used to update an existing statement on adjuvant RT. The balance of the guideline statements were reaffirmed, and references added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases were found. Conclusions: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage RT. Clinicians should discuss possible short- and long-term side effects with patients in addition to the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multidisciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.",
author = "Pisansky, {Thomas M.} and Thompson, {Ian M.} and Valicenti, {Richard K} and D'Amico, {Anthony V.} and Shalini Selvarajah",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.prro.2019.04.008",
language = "English (US)",
volume = "9",
pages = "208--213",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Adjuvant and Salvage Radiation Therapy After Prostatectomy

T2 - ASTRO/AUA Guideline Amendment, Executive Summary 2018

AU - Pisansky, Thomas M.

AU - Thompson, Ian M.

AU - Valicenti, Richard K

AU - D'Amico, Anthony V.

AU - Selvarajah, Shalini

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Purpose: The purpose of this amendment is to incorporate newly published literature into the original American Society for Radiation Oncology/American Urological Association Adjuvant and Salvage Radiotherapy After Prostatectomy Guideline and provide an updated clinical framework for clinicians. Methods and Materials: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published between January 1990 and December 2017. Two new key questions were added: one on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation after radical prostatectomy. Results: A new statement on the use of hormone therapy with salvage radiation therapy (RT) after radical prostatectomy was added, and long-term data were used to update an existing statement on adjuvant RT. The balance of the guideline statements were reaffirmed, and references added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases were found. Conclusions: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage RT. Clinicians should discuss possible short- and long-term side effects with patients in addition to the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multidisciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.

AB - Purpose: The purpose of this amendment is to incorporate newly published literature into the original American Society for Radiation Oncology/American Urological Association Adjuvant and Salvage Radiotherapy After Prostatectomy Guideline and provide an updated clinical framework for clinicians. Methods and Materials: The original systematic review yielded 294 studies published between January 1990 and December 2012. In April 2018, the guideline underwent an amendment and incorporated 155 references that were published between January 1990 and December 2017. Two new key questions were added: one on the use of genomic classifiers and the other on the treatment of oligo-metastases with radiation after radical prostatectomy. Results: A new statement on the use of hormone therapy with salvage radiation therapy (RT) after radical prostatectomy was added, and long-term data were used to update an existing statement on adjuvant RT. The balance of the guideline statements were reaffirmed, and references added to the existing literature base. A discussion on the use of genomic classifiers as a risk stratification tool was added to the future research discussion. No relevant data on oligo-metastases were found. Conclusions: Hormone therapy should be offered to patients who have had radical prostatectomy and who are candidates for salvage RT. Clinicians should discuss possible short- and long-term side effects with patients in addition to the potential benefits of preventing recurrence. The decision to use hormone therapy should be made by the patient and a multidisciplinary team of providers with full consideration of the patient's history, values, preferences, quality of life, and functional status.

UR - http://www.scopus.com/inward/record.url?scp=85067548696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067548696&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2019.04.008

DO - 10.1016/j.prro.2019.04.008

M3 - Article

VL - 9

SP - 208

EP - 213

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

IS - 4

ER -